EUVIMEDEUVIMED entdecken
Crossref

Palbociclib inhibits the progression of head and neck cancer and improves the Cetuximab response under specific condition in vitro and in vivo

Ruichen Li, Qi Wang, Yang Zhao, Yi Zhu, Xiaoshen Wang

Molecular Biology Reports · 2024

DOI: 10.1007/s11033-024-09423-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Biology Reports, 2024. Verfasst von Ruichen Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Eye & ENT Hospital of Fudan University, 83 Fenyang Road, Shanghai, 200031, China. Hauptthemen laut MEDLINE: Papillomavirus Infections, Head and Neck Neoplasms, Piperazines, Pyridines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Medical Guidance Project of the Shanghai Science and Technology Commission, National Key R&D Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: In head and neck squamous cell carcinoma (HNSCC) with human papillomavirus (HPV)-negative, deregulation of cell cycle is partly due to inactivation of p16INK4 and overexpression of cyclin D1. Here we investigated the in vitro and in vivo effects of the CDK4/6 inhibitor Palbociclib alone or combined with EGFR inhibitor Cetuximab in HNSCC. METHODS AND RESULTS: CCK-8, soft agar assay, colony formation assay, wound healing assay and transwell assay, β-galactosidase assay, western blotting, and cell-derived xenografts were used to investigated the in vitro and in vivo activity of drugs. Cell viability and colony formation decreased in a dose-dependent manner in Tu686, AMC-HN8, and Fadu cells under Palbociclib treatment. Palbociclib remarkably inhibited migration, invasion and the expression MMP-9 in HNSCC cells. Palbociclib also induced senescence. Palbociclib caused the dephosphorylation of RB but increased the cyclin D1 level in a dose-dependent manner. Moreover, combination with Cetuximab could significantly prevent the induction of cyclin D1 and activation of EGFR signals from Palbociclib treatment. Nevertheless, only within the range of certain concentrations, a synergistic inhibitory effect on cell growth was observed when combined with Palbociclib and Cetuximab. Although the synergistic effect in Palbociclib/Cetuximab combined therapy was comparable to that in traditional chemotherapeutic regimens (cisplatin/Cetuximab) in Fadu tumor xenograft, the combination therapy was less active than Cetuximab monotherapy in Tu686 tumor xenograft. CONCLUSION: In HPV-negative HNSCC, CDK4/6 inhibitor shows promising anti-tumor effects, which exhibits a synergistic effect when combined with EGFR inhibitor only in specific drug concentration and mouse model.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Papillomavirus InfectionsHead and Neck NeoplasmsPiperazinesPyridinesAnimalsMiceHumansCetuximabSquamous Cell Carcinoma of Head and NeckCyclin D1ErbB ReceptorsCell Line, Tumor

Stichwörter der Autor:innen

CetuximabHead and neck squamous cell carcinomaHuman papillomavirus-negativePalbociclibSynergistic effect

Substanzen

CetuximabpalbociclibCyclin D1ErbB ReceptorsPiperazinesPyridines

Autor:innen und Institutionen

  • Department of Radiation Oncology, Eye & ENT Hospital of Fudan University, 83 Fenyang Road, Shanghai, 200031, China.
  • Department of Plastic Surgery, Jiahui International Hospital, Jiahui Health, Shanghai, 200031, China.
  • Department of Radiation Oncology, Eye & ENT Hospital of Fudan University, 83 Fenyang Road, Shanghai, 200031, China. zhuyi1113@hotmail.com.
  • Department of Radiation Oncology, Eye & ENT Hospital of Fudan University, 83 Fenyang Road, Shanghai, 200031, China. xiaoshen.wang@fdeent.org.

Förderung

  • Medical Guidance Project of the Shanghai Science and Technology Commission
  • National Key R&D Program of China

Zitieren

APA

Li, R., Wang, Q., Zhao, Y., Zhu, Y., & Wang, X. (2024). Palbociclib inhibits the progression of head and neck cancer and improves the Cetuximab response under specific condition in vitro and in vivo. Molecular Biology Reports. https://doi.org/10.1007/s11033-024-09423-7

Vancouver

Li R, Wang Q, Zhao Y, Zhu Y, Wang X. Palbociclib inhibits the progression of head and neck cancer and improves the Cetuximab response under specific condition in vitro and in vivo. Molecular Biology Reports. 2024. doi:10.1007/s11033-024-09423-7

BibTeX
@article{Li2024,
  author = {Li, Ruichen and Wang, Qi and Zhao, Yang and Zhu, Yi and Wang, Xiaoshen},
  title = {Palbociclib inhibits the progression of head and neck cancer and improves the Cetuximab response under specific condition in vitro and in vivo},
  journal = {Molecular Biology Reports},
  year = {2024},
  doi = {10.1007/s11033-024-09423-7}
}
Kostenlos starten →